One of the more noticeable atrocities I saw recently walking through the airport in Indianapolis—actually worse than the obese women wearing spandex—were the Ozempic victims. You couldn’t help but notice them. Not a lot, but there were definitely a few people who looked like they left 40 pounds in the parking garage. Ozempic, Wegovy, Mounjaro, Zepbound—the GLP-1 revolution has become more of a cultural event. Which one are you taking?
But, not without the backlash: “Yeah, but those drugs eat your muscle.”
Olena/Adobe Stock
Do GLP-1 Drugs Like Ozempic and Zepbound Cause Muscle Loss?
Well, sort of. But not exactly. A new 2026 meta-analysis looked at 20 randomized trials involving 15,782 people and compared lean-mass loss during treatment with semaglutide, tirzepatide and liraglutide against lifestyle-based weight loss. The numbers were remarkable. Lean tissue represented about 35% of weight lost with semaglutide, 25% with tirzepatide and 27% with liraglutide.
Sounds horrific. Until you look at what happened to people who lost weight the old-fashioned way.
How Can Lifters Prevent Muscle Loss While Taking GLP-1 Medications?
With lifestyle intervention alone, roughly 26% of the weight lost was lean mass. In other words, losing some lean tissue isn’t some peculiar evil inflicted by a GLP-1 molecule. It’s something humans tend to do when they lose a lot of weight by restricting a lot of calories.
When resistance training was incorporated into the lifestyle intervention, lean tissue accounted for only about 17.5% of the weight lost—the best preservation in the analysis.
This shouldn’t be shocking. Yet somehow we’ve spent several years pretending the only two choices are either taking a shot or eating a dry chicken breast and suffering. They aren’t mutually exclusive.
The real problem with GLP-1 drugs from a bodybuilding/fitness/athletic perspective isn’t that they contain some mystical muscle-dissolving ingredient. It’s that they can make eating extraordinarily easy to avoid. That’s their job. If appetite goes into the toilet, calories go down. Which probably means protein is going down. And training intensity will probably also go down. And if you lose 50 pounds while providing your body no compelling reason to retain expensive skeletal muscle, your body isn’t going to be sentimental about your quads. You will literally diet your ass off.
The Real Risk of GLP-1 Medications and Muscle Growth
There is another wrinkle. Lean mass isn’t synonymous with contractile muscle tissue. DXA-derived “lean mass”measurements (body fat percentage) include water and other non-fat tissue. Recent reviews also report that while GLP-1 treatment reduces some lean mass, fat loss generally exceeds lean-tissue loss, and available evidence has not consistently shown corresponding deterioration in strength or physical function. So both camps need to holster their Glocks.
The GLP-1 evangelists shouldn’t pretend dramatic weight loss is automatically perfect body composition. The anti-GLP-1 crowd shouldn’t pretend semaglutide crawls into your bedroom at night and eats your biceps.
Lose substantial body weight and muscle preservation becomes part of the job.
Lift hard. Eat adequate protein. Monitor body composition and not the scale. And remember that being 190 pounds with more functioning muscle may be a vastly better outcome than being 175 simply because 175 is a lower number. You can hack off an arm and effect a “weight” loss.
And this subject isn’t going away. Just today, Novo Nordisk reported that a late-stage semaglutide trial in children ages 6 to under 12 met its primary BMI endpoint; 40.4% of treated children were no longer classified as having obesity after 68 weeks assuming full adherence. The children also received dietary and physical-activity intervention. Semaglutide is not currently FDA-approved for obesity in children under 12; Wegovy’s existing pediatric obesity indication begins at age 12.
We’re entering an era in which pharmacological weight management may begin younger, last longer and become increasingly commonplace.
It all boils down to the question no longer being, “How much weight did you lose?”
